कंपनी लोड हो रही है
Just reported
Q3 2026 results
From Sutro Biopharma's results release of 12 नवंबर 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
$9.1M
-6.1% y/y
-7.5% q/qGuided
—
No guide given
Operating income, GAAP
Actual
-$22M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Sutro Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15.4BA
HALOHalozyme Therapeutics, Inc.$11.5BA+
TECHBIO-Techne Corp$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
BIIBBiogen Inc.28 अक्टू॰ 2026BAGraded B, now A
Sutro Biopharma, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
